Search results
Showing 16 to 30 of 36 results for clopidogrel
Stroke and ischaemic attack: anti-platelet or anticoagulation (IND133)
This indicator covers the percentage of patients with a stroke shown to be non-haemorrhagic, or a history of TIA, who have a record in the preceding 12 months that an anti-platelet agent, or an anti-coagulant is being taken. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM94.
Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)
This guideline covers interventions in the acute stage of a stroke or transient ischaemic attack (TIA). It offers the best clinical advice on the diagnosis and acute management of stroke and TIA in the 48 hours after onset of symptoms.
This indicator covers the percentage of patients with peripheral arterial disease with a record in the preceding 15 months that aspirin or an alternative antiplatelet is being taken. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM33
Atrial fibrillation - clopidogrel (in combination with aspirin) [ID95]
Discontinued [GID-TAG416]
Bioresorbable stent implantation to treat coronary artery disease (IPG732)
Evidence-based recommendations on bioresorbable stent implantation to treat coronary artery disease in adults. This involves implanting a stent (small tube) into a narrowed artery to widen it.
View recommendations for IPG732Show all sections
urothelial tract - vinflunine 23 May 2011 TA090 Vascular disease - clopidogrel and dipyridamole 25 February 2005 Back to top Rejected
Overprescribing of rivaroxaban in non-atrial fibrillation patients in primary care
events in acute coronary syndrome (with aspirin alone or aspirin and clopidogrel) 2.5mg twice daily for 12 months usually . (NICE TA335)...
Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke (DG41)
Evidence-based recommendations on implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke
NICE launches second consultation on genetic testing to guide treatment after a stroke
People could be offered a genetic test in the immediate period after having a stroke to help identify the most suitable treatment to reduce their risk of further strokes.
Heart valve disease presenting in adults: investigation and management (NG208)
This guideline covers investigation and management of heart valve disease presenting in adults. It aims to improve quality of life and survival for people with heart valve disease through timely diagnosis and appropriate intervention.
This evidence summary has been withdrawn and NICE accredited guidance is available from the Royal College of Physicians.
This guideline covers assessment and early management of head injury in babies, children, young people and adults. It aims to ensure that people have the right care for the severity of their head injury, including direct referral to specialist care if needed.
Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome (TA80)
This guidance has been replaced by recommendations 1.3.4 to 1.3.8 in NICE guideline CG94 and by recommendation 1.3.18 in NICE guideline CG172.
Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events (TA90)
This guideline has been updated and replaced by NICE technology appraisal 210.
ClearWay RX for drug delivery to coronary artery thrombotic lesions (MIB55)
NICE has developed a medtech innovation briefing (MIB) on ClearWay RX for drug delivery to coronary artery thrombotic lesions